A new discovery involving cytotoxic T cells in human cancer therapy

A new discovery involving cytotoxic T cells in human cancer therapy

Recent research proves that T cells can hunt and kill cancer cells by overloading them with toxic weapons.

Cytotoxic T lymphocytes are part of our immune system. White blood cells recognize and eliminate threats, including cancer cells and cells infected with invasive viruses such as SARS-CoV-2, which causes COVID-19. The ability to kill target cells is strictly regulated and depends on the stimulation of the appropriate receptors.

The discovery of Professor Gillian Griffiths (CIMR) and Dr. Julien Prudent (MBU) groups is a breakthrough in the treatment of cancer. The study shows that billions of T cells are sent by the immune system to “fight” cancer cells. Each works like a trained killer – it binds to a cancer cell and then releases a toxic load. But that’s not all. New research shows that cells kill and then reload their weapons to kill again.

 

Weapon replenishment is possible thanks to mitochondria which is the powerhouse of the cell. Mitochondria not only provide the cell with energy – they also regulate the rate of killing to the rate of producing new proteins in such a way that the cargo does not damage the T cells themselves. In this way, T cells can work effectively under harsh conditions.

 

This study improves the efficiency of the design of cytotoxic T cells to serially kill cancer cells.

 

Such studies are complex and require state of the art facilities. In EBI our animal facility is equipped to handle work needed to achieve groundbreaking discoveries!

Let’s talk!

 


 

See more

ISO 10993-1:2025: Enhanced Characterization, Clearer Risk Logic

The 2025 revision keeps biological evaluation firmly inside ISO 14971 risk management and across the full device life cycle. Your…

ISO 10993-1:2025: Risk Management Integration and Exposure Duration

ISO 10993-1:2025 embeds the biological evaluation within ISO 14971’s risk-management framework. The standard explicitly requires identifying biological hazards, estimating their…

Preparing for Biocompatibility Testing: Strategic Considerations for Medical Device Manufacturers

Biocompatibility testing is essential for every medical device, ensuring safety, regulatory approval, and market success. The process, however, can be…

In Vitro & In Vivo: Strategic Insights for Medical Device Leaders

Biocompatibility testing is not just a regulatory requirement—it is a cornerstone of medical device safety, market approval, and long-term trust….

Biocompatibility Requirements for Wearable Medical Devices: Unique Considerations

Wearable medical devices are transforming healthcare with continuous monitoring, real-time diagnostics, and improved patient engagement. However, their design introduces distinct…

Proactive Planning: Combining Biocompatibility with Other Preclinical Testing Needs

Biocompatibility testing is a vital part of preclinical evaluation, but it’s just one piece of the larger puzzle. Manufacturers often…